The MARGOT/TBCRC052 trial failed to show a significant improvement in pathologic complete response (pCR) rates with margetuximab compared with trastuzumab in patients with early-stage HER2-positive ...

Sorry, Hollywood. Indie studios have officially taken over the poster game. Of the 25 films listed below, I can count the number of legacy studios on one hand (even ...

The anti-Trump posters, which depict the president-elect with the words “Keep DC trash free,” initially appeared to be created as transit ads funded by the district’s government and were ...

Margetuximab is under clinical development by MacroGenics and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success ...